Compare TLSA & JELD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TLSA | JELD |
|---|---|---|
| Founded | 2013 | 1960 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Forest Products |
| Sector | Health Care | Basic Materials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 155.2M | 168.8M |
| IPO Year | 2017 | 2016 |
| Metric | TLSA | JELD |
|---|---|---|
| Price | $1.22 | $1.26 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $3.43 |
| AVG Volume (30 Days) | 108.5K | ★ 1.6M |
| Earning Date | 05-06-2025 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $3,211,181,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $2.31 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.73 | $1.24 |
| 52 Week High | $2.60 | $6.98 |
| Indicator | TLSA | JELD |
|---|---|---|
| Relative Strength Index (RSI) | 38.51 | 23.15 |
| Support Level | N/A | N/A |
| Resistance Level | $1.56 | $2.06 |
| Average True Range (ATR) | 0.09 | 0.13 |
| MACD | -0.01 | -0.02 |
| Stochastic Oscillator | 8.62 | 1.83 |
Tiziana Life Sciences Ltd is a clinical stage biotechnology company that specializes in developing transformative therapies for neurodegenerative and neuroinflammatory diseases. The company's clinical pipeline includes drug assets for Secondary Progressive Multiple Sclerosis, Alzheimer's, and ALS. Its flagship immunotherapeutic candidate, Foralumab (TZLS-401), which is a fully human anti-CD3 monoclonal antibody, is being developed for Non-Active Secondary Progressive Multiple Sclerosis, Alzheimer's and other CNS indications.
JELD-WEN Holding Inc is engaged in door and window manufacturing. The company designs, produces, and distributes interior and exterior building products, offering a selection of doors, windows, walls, and related products. The products are used in the new construction of residential and non-residential buildings. The firm's operating segments are North America, and Europe. It generates a majority of its revenue from North America.